These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15998426)

  • 1. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy.
    Lu JY; Chuang LM; Yang WS; Tai TY; Lai MY; Chen PJ; Kao JH; Lee CZ; Lee HS
    Liver Int; 2005 Aug; 25(4):752-9. PubMed ID: 15998426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C.
    Tai TY; Lu JY; Chen CL; Lai MY; Chen PJ; Kao JH; Lee CZ; Lee HS; Chuang LM; Jeng YM
    J Endocrinol; 2003 Sep; 178(3):457-65. PubMed ID: 12967337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
    J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.
    Manolakopoulos S; Bethanis S; Liapi C; Stripeli F; Sklavos P; Margeli A; Christidou A; Katsanika A; Vogiatzakis E; Tzourmakliotis D; Theocharis S
    BMC Gastroenterol; 2007 May; 7():17. PubMed ID: 17540037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
    Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations of serum levels of adiponectin and resistin in chronic viral hepatitis.
    Durazzo M; Belci P; Niro G; Collo A; Grisoglio E; Ambrogio V; Spandre M; Fontana R; Gambino R; Cassader M; Bo S
    J Endocrinol Invest; 2013 Sep; 36(8):600-5. PubMed ID: 23449040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
    Saad Y; Ahmed A; Saleh DA; Doss W
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
    Stancek D; Fuchsberger N; Oltman M; Schmeisser H; Kontsek P; Jahnová E; Hajnická V
    Acta Virol; 2001; 45(5-6):287-92. PubMed ID: 12083327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
    Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.
    Villa E; Grottola A; Buttafoco P; Colantoni A; Bagni A; Ferretti I; Cremonini C; Bertani H; Manenti F
    Am J Gastroenterol; 2001 Oct; 96(10):2973-7. PubMed ID: 11693335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preliminary results of interferon alpha-2a and lamivudine combination therapy regimen in children with chronic hepatitis B].
    Aşik Akman S; Cokçeken Okçu S; Anil OH; Köse S; Bakiler AR
    Mikrobiyol Bul; 2006; 40(1-2):47-53. PubMed ID: 16775956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA
    Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
    Zampino R; Marrone A; Durante Mangoni E; Santarpia L; Sica A; Tripodi MF; Utili R; Ruggiero G; Adinolfi LE
    J Med Virol; 2004 May; 73(1):33-7. PubMed ID: 15042645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.